Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
To determine the efficacy and tolerability of deferasirox in the treatment of Porphyria
Cutanea Tarda.
Primary objective - the elimination of all blistering within 6 months of treatment.
Secondary objective - decrease in total body iron levels.